Wing Lee Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wing Lee Chan has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Agnes Ellinghaus
Julius Wolff Institute, Berlin Institute of Health at Charité-Universitätsmedizin Berlin , Berlin 13353
2 shared publicationsAndré Bembennek
Institute for Computational Systems Biomedicine, University of Hamburg , Hamburg 22761
2 shared publicationsRaphaela Fritsche-Guenther
Berlin Institute of Health at Charité-BIH Metabolomics , Berlin 10117
2 shared publications- Tanja Laske
Institute for Computational Systems Biology, University of Hamburg, Hamburg, Germany
2 shared publications - Uwe Kornak
Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany
2 shared publications - Alvin Chun-Hang Ma
Department of Health Technology and Informatics Hong Kong Polytechnic University Hong Kong China
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 114 (11) , e70161
Topology–Process Interactions During Fabrication Shape Triply Periodic Minimal Surface Microarchitecture and Osteogenic Outcomes in Melt‐Extruded Polycaprolactone Scaffolds
Additive manufacturing enables bone scaffolds with customizable pore geometry and curvature. Although triply periodic minimal surface (TPMS) architectures can influence osteogenic differentiation, scaffold performance is often interpreted from CAD‐defined topology, while melt extrusion may generate distinct print‐realized microarchitectures. Here, polycaprolactone constructs were fabricated by melt extrusion‐based additive manufacturing as 2.5D discs printed with 200 or 400 μm nozzles to modulate strand‐scale print geometry and as 3D TPMS scaffolds in diamond, double diamond, and gyroid architectures. Murine D1 mesenchymal stromal cells were cultured under growth or osteogenic conditions and assessed by CCK‐8 metabolic activity, PicoGreen dsDNA quantification, alkaline phosphatase activity, Alizarin Red staining, and qRT‐PCR. In 2.5D cultures, S200 and S400 produced no significant differences in metabolic activity, dsDNA content, ALP activity, or mineralization, indicating that the tested differences in strand width and height did not measurably affect osteogenic outcomes. Micro‐CT analysis of 3D scaffolds showed architecture‐dependent differences in the printed microarchitecture under identical process conditions. DDia exhibited increased wall thickness, reduced pore separation, lower porosity, and higher scaffold surface density than Dia and Gyr. In 3D cultures, Dia and Gyr supported stronger osteogenic responses than DDia, while nonnormalized dsDNA data indicated that these differences were not simply explained by a major difference in total cell content. Gyr showed higher Sost expression, suggesting greater progression toward osteocyte maturation. These findings identify print‐realized microarchitecture as an important link between CAD‐defined TPMS topology and osteogenic outcome in melt‐extruded PCL scaffolds.
- 9 November 2026
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 114 (11) , e70161
Open AccessTopology–Process Interactions During Fabrication Shape Triply Periodic Minimal Surface Microarchitecture and Osteogenic Outcomes in Melt‐Extruded Polycaprolactone Scaffolds
Additive manufacturing enables bone scaffolds with customizable pore geometry and curvature. Although triply periodic minimal surface (TPMS) architectures can influence osteogenic differentiation, scaffold performance is often interpreted from CAD‐defined topology, while melt extrusion may generate distinct print‐realized microarchitectures. Here, polycaprolactone constructs were fabricated by melt extrusion‐based additive manufacturing as 2.5D discs printed with 200 or 400 μm nozzles to modulate strand‐scale print geometry and as 3D TPMS scaffolds in diamond, double diamond, and gyroid architectures. Murine D1 mesenchymal stromal cells were cultured under growth or osteogenic conditions and assessed by CCK‐8 metabolic activity, PicoGreen dsDNA quantification, alkaline phosphatase activity, Alizarin Red staining, and qRT‐PCR. In 2.5D cultures, S200 and S400 produced no significant differences in metabolic activity, dsDNA content, ALP activity, or mineralization, indicating that the tested differences in strand width and height did not measurably affect osteogenic outcomes. Micro‐CT analysis of 3D scaffolds showed architecture‐dependent differences in the printed microarchitecture under identical process conditions. DDia exhibited increased wall thickness, reduced pore separation, lower porosity, and higher scaffold surface density than Dia and Gyr. In 3D cultures, Dia and Gyr supported stronger osteogenic responses than DDia, while nonnormalized dsDNA data indicated that these differences were not simply explained by a major difference in total cell content. Gyr showed higher Sost expression, suggesting greater progression toward osteocyte maturation. These findings identify print‐realized microarchitecture as an important link between CAD‐defined TPMS topology and osteogenic outcome in melt‐extruded PCL scaffolds.
- Open Access
- 22 January 2026
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 13
Polycaprolactone scaffolds promote a regeneration-supportive metabolic response attenuated in diabetes
Scaffold-guided bone regeneration (SGBR) is a promising strategy for repairing large bone defects. However, its efficacy is markedly reduced in diabetes. Here, we used non-diabetic and diabetic Zucker Diabetic Fatty (ZDF) rats with sham-operated, empty-defect and scaffold-treated groups to examine how host metabolic state influences the regenerative performance of 3D-printed polycaprolactone (PCL) scaffolds in critical-sized femoral defects. Targeted metabolomics of plasma and femoral midshaft revealed a distinct diabetic signature that was characterized by carbohydrate accumulation and broad amino acid dysregulation. In non-diabetic rats, PCL scaffolds enhanced bone regeneration and were associated with a local metabolic response consistent with a regeneration-supportive increase in energy and substrate availability, including glutamate-related metabolism. In diabetic rats, empty defects showed elevated branched-chain amino acids (BCAAs) and reduced glutamine, together with limited bone regeneration. Although scaffold treatment partially normalized BCAAs in diabetic rats, glutamate was not restored and the regenerative benefit of scaffold implantation was lost. These data indicate that SGBR is associated with a regeneration-supportive metabolic response in non-diabetic bone defects, whereas this response is blunted in the diabetic host. This study underscores the need for biomaterial strategies better matched to metabolically compromised host conditions, such as diabetes, to enable effective scaffold-guided regeneration.
- 22 January 2026
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 13
Open AccessPolycaprolactone scaffolds promote a regeneration-supportive metabolic response attenuated in diabetes
Scaffold-guided bone regeneration (SGBR) is a promising strategy for repairing large bone defects. However, its efficacy is markedly reduced in diabetes. Here, we used non-diabetic and diabetic Zucker Diabetic Fatty (ZDF) rats with sham-operated, empty-defect and scaffold-treated groups to examine how host metabolic state influences the regenerative performance of 3D-printed polycaprolactone (PCL) scaffolds in critical-sized femoral defects. Targeted metabolomics of plasma and femoral midshaft revealed a distinct diabetic signature that was characterized by carbohydrate accumulation and broad amino acid dysregulation. In non-diabetic rats, PCL scaffolds enhanced bone regeneration and were associated with a local metabolic response consistent with a regeneration-supportive increase in energy and substrate availability, including glutamate-related metabolism. In diabetic rats, empty defects showed elevated branched-chain amino acids (BCAAs) and reduced glutamine, together with limited bone regeneration. Although scaffold treatment partially normalized BCAAs in diabetic rats, glutamate was not restored and the regenerative benefit of scaffold implantation was lost. These data indicate that SGBR is associated with a regeneration-supportive metabolic response in non-diabetic bone defects, whereas this response is blunted in the diabetic host. This study underscores the need for biomaterial strategies better matched to metabolically compromised host conditions, such as diabetes, to enable effective scaffold-guided regeneration.
- Open Access
- 20 August 2025
- Published by Springer Nature in Nature
- Vol. 646 (8083) , 218-226
A missing enzyme-rescue metabolite as cause of a rare skeletal dysplasia
Living cells depend on an intricate network of chemical reactions catalysed by enzymes, which sometimes make mistakes that lead to their inactivation. Here we report a metabolite-based mechanism for preserving enzyme function in an unfavourable environment. We found that the enzyme TGDS produces UDP-4-keto-6-deoxyglucose, a mimic of the reaction intermediate of the enzyme UXS1, which regenerates the essential cofactor NAD+ within the catalytic pocket of UXS1 by completing its catalytic cycle. Thus, the production of an ‘enzyme-rescue metabolite’ by TGDS represents a mechanism for maintaining the activity of an enzyme in a subcellular compartment where NAD+ is scarce. Using a combination of in vitro and in vivo studies, we demonstrate that the inability to produce sufficient amounts of this enzyme-rescue metabolite leads to the inactivation of UXS1, impairing the synthesis of specific glycans that are crucial for skeletal development. This provides an explanation for the development of the hereditary skeletal disorder Catel–Manzke syndrome in individuals with TGDS deficiency. Defects in similar protective layers might contribute to metabolic changes in other diseases that cannot be explained with common concepts in metabolic biochemistry.
- 20 August 2025
- Published by Springer Nature in Nature
- Vol. 646 (8083) , 218-226
Open AccessA missing enzyme-rescue metabolite as cause of a rare skeletal dysplasia
Living cells depend on an intricate network of chemical reactions catalysed by enzymes, which sometimes make mistakes that lead to their inactivation. Here we report a metabolite-based mechanism for preserving enzyme function in an unfavourable environment. We found that the enzyme TGDS produces UDP-4-keto-6-deoxyglucose, a mimic of the reaction intermediate of the enzyme UXS1, which regenerates the essential cofactor NAD+ within the catalytic pocket of UXS1 by completing its catalytic cycle. Thus, the production of an ‘enzyme-rescue metabolite’ by TGDS represents a mechanism for maintaining the activity of an enzyme in a subcellular compartment where NAD+ is scarce. Using a combination of in vitro and in vivo studies, we demonstrate that the inability to produce sufficient amounts of this enzyme-rescue metabolite leads to the inactivation of UXS1, impairing the synthesis of specific glycans that are crucial for skeletal development. This provides an explanation for the development of the hereditary skeletal disorder Catel–Manzke syndrome in individuals with TGDS deficiency. Defects in similar protective layers might contribute to metabolic changes in other diseases that cannot be explained with common concepts in metabolic biochemistry.
- Open Access
- 2 May 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 199, 108-119
Endogenous dysregulated energy and amino acid metabolism delay scaffold-guided large volume bone regeneration in a diabetic rat model with Leptin receptor deficiency
- 2 May 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 199, 108-119
Open AccessEndogenous dysregulated energy and amino acid metabolism delay scaffold-guided large volume bone regeneration in a diabetic rat model with Leptin receptor deficiency
- Open Access
- 5 September 2024
- Published by Wiley in Aging Cell
- Vol. 23 (12) , e14322
Targeting TGF‐β signaling, oxidative stress, and cellular senescence rescues osteoporosis in gerodermia osteodysplastica
GORAB is a key regulator of Golgi vesicle transport and protein glycanation. Loss of GORAB function in gerodermia osteodysplastica (GO) causes shortening of glycosaminoglycan chains, leading to extracellular matrix disorganization that results in wrinkled skin, osteoporosis and elevated TGF‐β signaling. In this study, we investigated the role of TGF‐β‐signaling, oxidative stress, and resulting cellular senescence in the osteoporosis phenotype of GO. Treatment of GorabPrx1 conditional knockouts with the TGF‐β neutralizing antibody 1D11 rescued the trabecular bone loss, indicating that TGF‐β overactivation causes osteoporosis in GO. Using an inducible knockout system, we demonstrated that TGF‐β dysregulation was not a cell‐intrinsic effect of GORAB inactivation, but a consequence of a disorganized extracellular matrix. Enhanced TGF‐β signaling caused elevated Nox4 expression in GorabPrx1 mutants and in GO patients' fibroblasts, resulting in overproduction of mitochondrial superoxide. The resulting oxidative stress was detected in GORAB null cells and also in wildtype bystander cells. The same effect was observed in zebrafish after TALEN‐mediated gorab inactivation, indicating that the pathway is evolutionarily conserved. Treating GorabPrx1 mutants with the antioxidant N‐acetylcysteine ameliorated the osteoporosis phenotype. TGF‐β induced oxidative stress coincided with accumulation of DNA damage and elevated expression of senescence markers. Inactivation of Cdkn2a in the GorabPrx1 rescued the osteoporosis phenotype. Reduced colony formation and altered subpopulations of bone marrow stromal cells were normalized upon inactivation of Cdkn2a, thus further demonstrating the relevance of cellular senescence in the pathogenesis. Our results shed light on the causative role of a TGF‐β‐Nox4‐senescence axis and therapeutic strategies for GO.
- 5 September 2024
- Published by Wiley in Aging Cell
- Vol. 23 (12) , e14322
Open AccessTargeting TGF‐β signaling, oxidative stress, and cellular senescence rescues osteoporosis in gerodermia osteodysplastica
GORAB is a key regulator of Golgi vesicle transport and protein glycanation. Loss of GORAB function in gerodermia osteodysplastica (GO) causes shortening of glycosaminoglycan chains, leading to extracellular matrix disorganization that results in wrinkled skin, osteoporosis and elevated TGF‐β signaling. In this study, we investigated the role of TGF‐β‐signaling, oxidative stress, and resulting cellular senescence in the osteoporosis phenotype of GO. Treatment of GorabPrx1 conditional knockouts with the TGF‐β neutralizing antibody 1D11 rescued the trabecular bone loss, indicating that TGF‐β overactivation causes osteoporosis in GO. Using an inducible knockout system, we demonstrated that TGF‐β dysregulation was not a cell‐intrinsic effect of GORAB inactivation, but a consequence of a disorganized extracellular matrix. Enhanced TGF‐β signaling caused elevated Nox4 expression in GorabPrx1 mutants and in GO patients' fibroblasts, resulting in overproduction of mitochondrial superoxide. The resulting oxidative stress was detected in GORAB null cells and also in wildtype bystander cells. The same effect was observed in zebrafish after TALEN‐mediated gorab inactivation, indicating that the pathway is evolutionarily conserved. Treating GorabPrx1 mutants with the antioxidant N‐acetylcysteine ameliorated the osteoporosis phenotype. TGF‐β induced oxidative stress coincided with accumulation of DNA damage and elevated expression of senescence markers. Inactivation of Cdkn2a in the GorabPrx1 rescued the osteoporosis phenotype. Reduced colony formation and altered subpopulations of bone marrow stromal cells were normalized upon inactivation of Cdkn2a, thus further demonstrating the relevance of cellular senescence in the pathogenesis. Our results shed light on the causative role of a TGF‐β‐Nox4‐senescence axis and therapeutic strategies for GO.